Neurotoxin Science | Mental Health
EXPANDING THEPOSSIBILITIES OFNEUROTOXIN MEDICINE.
Object Pharma is a specialized neurotoxin biotechnology company dedicated to advancing mental and brain health, beginning with Major Depressive Disorder (MDD) and our lead investigational program, OP01 — NextGen.
Object Pharma programs described on this website are investigational. OP01 is in preclinical development and has not been approved by the U.S. Food and Drug Administration or any other regulatory authority.
The Central Question
What if neurotoxinscould do more?
Neurotoxins are established medicines with important applications. Object Pharma is exploring whether differentiated neurotoxin biology can open additional therapeutic possibilities — starting with one question:
Could differentiated neurotoxin biology contribute to a new therapeutic approach in Major Depressive Disorder?
Depression needs
more ways forward.
MDD is Object Pharma's lead therapeutic focus — the reason the company's neurotoxin science exists.
~322M
people estimated to be living with depression globally in 2023
$12T
projected cumulative global macroeconomic burden, 2025–2050
~0.46%
estimated annual burden as a share of global GDP
Source: Cao Z. et al., Nature Medicine, 2026 — global burden research, not OP01 evidence
Read the studyThe human burden
Depression shapes daily life — energy, work, relationships and hope. Its impact extends far beyond a diagnosis, into families, workplaces and entire economies.
Limits of existing approaches
A substantial proportion of patients do not achieve adequate or sustained relief with existing treatments. For many, care remains a process of trial, waiting and compromise.
Why new mechanisms matter
Progress in depression has historically come from new mechanisms, not small variations on old ones. Approaches grounded in different biology remain a scientific priority.
A global health challenge. A global economic challenge.
A reason to ask new scientific questions.
The Trajectory
$0.0T
Projected cumulative global macroeconomic burden of depression, modeled 2025–2050. Cao Z. et al., Nature Medicine, 2026.
The cost accumulates. So does the need for new approaches.
How a neurotoxin
changes a signal.
01Neuron
A nerve cell communicates by releasing chemical messengers at specialized junctions.
02Synapse
At the neuromuscular junction, vesicles inside the nerve terminal release neurotransmitter across the cleft.
03Neurotoxin
A botulinum neurotoxin binds with high specificity to the surface of the nerve terminal.
04Cellular uptake
The neurotoxin is internalized into the neuron, where it acts on the vesicle-release machinery.
05Biological effect
Neurotransmitter release is modulated, changing the signal between nerve and muscle. Signaling recovers over time — a profile that differs between neurotoxins.
What if a locally administeredneurotoxin could influencemore than muscle?
Research involving botulinum neurotoxins has explored relationships between facial musculature, peripheral neural signaling and emotional processing. These observations have created a scientific hypothesis worth testing rigorously.
Facial musculature
Peripheral signaling
Neural processing
Emotional processing
Our first question
Major Depressive Disorder.
Presented as a scientific hypothesis under investigation — not established OP01 biology.
OP01 — NextGen
A different approach
to a difficult disease.
OP01 — NextGen is Object Pharma's lead investigational candidate, based on botulinum neurotoxin subtype A2, being developed initially for Major Depressive Disorder.
Object Pharma is investigating whether differentiated neurotoxin biology can translate into a clinically meaningful therapeutic profile for MDD.
Step 01
Local administration
Step 02
Targeted neuromuscular activity
Step 03
Peripheral / facial signaling
Step 04
Emotional processing hypothesis
Step 05
Clinical investigation
A local intervention.
A different biological hypothesis.
A new therapeutic question.
Not all botulinum neurotoxins
are biologically identical.
OP01 is based on botulinum neurotoxin subtype A2 — a distinct molecular subtype whose biological characteristics Object Pharma is investigating, without assumptions of superiority.
Dimension
Conventional BoNT/A1
BoNT/A2 — OP01 (investigational)
Cellular uptake
Characterized in approved products
Differential neuronal uptake reported in preclinical research
Preclinical observationLocalization
Established localized neuromuscular activity
Localization profile under preclinical investigation
Scientific hypothesisSpread
Established for approved products
Under investigation
[OBJECT PHARMA CONFIRMATION REQUIRED]Onset
Established kinetic profile
Differential kinetics observed in experimental models
Preclinical observationDuration
Established duration profile
Duration profile under preclinical investigation
Scientific hypothesisBiological characteristics
Well-characterized serotype A1 complex
Distinct molecular subtype; characterization ongoing
Scientific hypothesisA2 characteristics shown are preclinical observations or scientific hypotheses under investigation. They are not clinical claims, do not describe approved OP01 properties, and imply no superiority over any approved product.
The hypothesis
didn't begin with us.
Clinical research involving other botulinum neurotoxin products has generated evidence supporting further investigation of the relationship between facial neuromuscular modulation and depressive symptoms.
Early observations
Initial clinical observations and case-series research explored botulinum toxin A in depression.
Finzi & Wasserman, Dermatologic Surgery, 2006
Randomized controlled research
Randomized, placebo-controlled studies examined botulinum neurotoxin injection in patients with depression.
Wollmer et al., J Psychiatr Res, 2012 · Finzi & Rosenthal, J Psychiatr Res, 2014
Larger Phase 2 investigation
Larger multi-center randomized research further investigated the approach.
Citation pending editorial review
Meta-analyses
Pooled analyses and meta-analyses evaluated the accumulating body of evidence.
Magid et al., Pharmacopsychiatry, 2015 · further analyses pending review
Mechanistic research
Research into facial feedback and emotional proprioception explored possible mechanisms.
Citations pending editorial review
Object Pharma / OP01
Preclinical investigation of a differentiated neurotoxin candidate for Major Depressive Disorder.
Investigational — preclinical stage
Important disclosure: The referenced studies evaluated other botulinum neurotoxin products and do not constitute clinical evidence for OP01.
MDD is our lead indication.The science may go further.
Botulinum neurotoxins are a proven therapeutic class with applications across multiple therapeutic and aesthetic areas. Object Pharma's broader scientific interest follows from its neurotoxin capabilities — mental health remains the priority.
This is an established therapeutic class. Object is exploring its next frontier.
Broader applications represent scientific optionality arising from Object Pharma's neurotoxin capabilities — not active clinical programs.
Seven serotypes.
Different biology.
A platform for discovery.
Object Pharma's understanding of neurotoxin biology is grounded in Metabiologics — its specialized neurotoxin company in Madison, Wisconsin, with more than 25 years inside neurotoxin science and research-grade materials spanning botulinum neurotoxin serotypes A through G.
Depth across the full toxin family reinforces the credibility of Object Pharma's broader neurotoxin ambitions.
Explore the toxin family — A through G
Botulinum neurotoxin serotype A
The most extensively characterized serotype, and the basis of the first approved therapeutic neurotoxin products.
Research-use material — not a clinical product
Access changes what you can discover.
From specialized knowledge to investigational medicine.
01
Toxin biology
Deep understanding of neurotoxin structure, serotypes and behavior.
02
Characterization
Rigorous analytical and biological characterization of candidates.
03
Translational science
Connecting biological differences to therapeutic questions.
04
Proprietary candidates
Differentiated investigational neurotoxins, led by OP01 — NextGen.
05
Clinical development
Disciplined advancement toward human studies.
06
Medicine
The objective: meaningful new options for patients.
Capability areas shown for illustration; not every step is performed internally.
One lead program.
A platform behind it.
Lead
OP01 — NextGen
Major Depressive Disorder
Mental & brain health
Preclinical
Platform
Selected neurotoxin development opportunities. Program details pending corporate approval.
OP02
Pending approval
Pending approval
Pending approval
OP03
Pending approval
Pending approval
Pending approval
Broader applications
Potential therapeutic and aesthetic applications arising from differentiated neurotoxin biology. Exploratory — not active clinical programs.
Future possibilities arising from Object Pharma's neurotoxin science and the ObNowa European platform — communicated as scientific optionality, not as disclosed development programs.
Three organizations.
One connected capability.
Metabiologics
Madison, Wisconsin
Neurotoxin science & specialized capabilities
- Serotypes A–G research materials
- Production know-how
- Scientific infrastructure
- Institutional neurotoxin knowledge
Object Pharma
Aliso Viejo, California & Madison, Wisconsin
Neurotoxin innovation & therapeutic development
- Mental & brain health mission
- OP01 — NextGen — MDD
- Differentiated neurotoxin candidates
- Global opportunities
ObNowa Pharma
Warsaw, Poland
European development & commercialization
- European clinical development
- Regulatory strategy & partnering
- Medical aesthetics — incl. licensed hair & eyebrow programs
- Commercialization
The companies of the Object ecosystem operate distinct programs; not every program is shared between the three companies. ObNowa program details are described at a high level only.
Building the next chapter
of neurotoxin medicine.
Object Pharma welcomes discussions with pharmaceutical, biotechnology, academic and strategic partners interested in advancing neurotoxin science and therapeutic innovation.
P01
Therapeutic development
- ·Co-development
- ·Licensing
- ·Indication partnerships
P02
Scientific collaboration
- ·Translational research
- ·Academic collaborations
- ·Neurotoxin biology
P03
Development capabilities
- ·Process development
- ·Specialized neurotoxin expertise
- ·Selected ecosystem capabilities
P04
Commercial opportunities
- ·Regional partnerships
- ·Selected portfolio opportunities
- ·Medical-aesthetics opportunities through the appropriate Object company
The minds behind
the science.
Advancing neurotoxin medicine requires scientific curiosity, deep expertise and a shared commitment to addressing unmet medical needs.
Building toward
clinical validation.
Object Pharma is advancing OP01 toward clinical development while building a differentiated neurotoxin platform designed to create multiple therapeutic opportunities.
Our Purpose
Help people.Minimize suffering.Follow the science.
Science is the mechanism. Patients are the reason.